Volume 26, Issue 3 (Iranian South Medical Journal 2024)
Iran South Med J 2024, 26(3): 134-154 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Bakhshi H, Soufizomorrod M, Soleimani M. Blood Parameters in Coronavirus Patients After Cell Therapy with Placenta-Derived Mesenchymal Stem Cells. Iran South Med J 2024; 26 (3) :134-154
URL: http://ismj.bpums.ac.ir/article-1-1851-en.html
URL: http://ismj.bpums.ac.ir/article-1-1851-en.html
1- Department of Hematology, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran
2- Department of Hematology, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran ,m.soufi@modares.ac.ir
2- Department of Hematology, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran ,
Abstract: (777 Views)
Background: With the emergence of SARS CoV-2, we have witnessed numerous deaths and injuries. Due to the possibility of emergence of new strains, there is a need to improve treatment approaches. There are reports on the application of placenta-derived mesenchymal stem cells (p-MSCs) as a therapeutic approach. In this study, we investigated the therapeutic effects of these cells in patients with COVID-19.
Materials and Methods: Nine patients with severe and critical COVID-19 and severe inflammatory condition admitted to the ICU were candidates for cell therapy. For each subject, three 1 x 106 injections of p-MSC (cell/kg) were administered intravenously. The clinical manifestations of the patients and the occurrence of potential early complications as well as the levels of blood and inflammatory and anti-inflammatory parameters before and after cell therapy were investigated.
Results: All treated patients tolerated the p-MSC injection and no acute side-effect was reported for the treatment. The PaO2/FiO2 level increased significantly in the patients after cell therapy. The analysis of the blood, inflammatory and anti-inflammatory parameters of the patients before and after cell therapy showed a significant decrease in the level of RBC and CRP, D-dimer, IL-6 and TNF-α and an increase in platelets and IL-10. The changes in WBC, lymphocytes, neutrophils, monocytes, Hb and PT and biochemical parameters in the serum, fibrinogen coagulation, PH, PCO2, Po2, HCO3 and O2 sat (%) were not statistically significant.
Conclusion: Based on the results, three intravenous injections of p-MSCs in severe and acute patients improved their inflammatory condition and clinical symptoms and had a significant effect on their inflammatory and blood parameters including RBC and platelet.
Materials and Methods: Nine patients with severe and critical COVID-19 and severe inflammatory condition admitted to the ICU were candidates for cell therapy. For each subject, three 1 x 106 injections of p-MSC (cell/kg) were administered intravenously. The clinical manifestations of the patients and the occurrence of potential early complications as well as the levels of blood and inflammatory and anti-inflammatory parameters before and after cell therapy were investigated.
Results: All treated patients tolerated the p-MSC injection and no acute side-effect was reported for the treatment. The PaO2/FiO2 level increased significantly in the patients after cell therapy. The analysis of the blood, inflammatory and anti-inflammatory parameters of the patients before and after cell therapy showed a significant decrease in the level of RBC and CRP, D-dimer, IL-6 and TNF-α and an increase in platelets and IL-10. The changes in WBC, lymphocytes, neutrophils, monocytes, Hb and PT and biochemical parameters in the serum, fibrinogen coagulation, PH, PCO2, Po2, HCO3 and O2 sat (%) were not statistically significant.
Conclusion: Based on the results, three intravenous injections of p-MSCs in severe and acute patients improved their inflammatory condition and clinical symptoms and had a significant effect on their inflammatory and blood parameters including RBC and platelet.
Keywords: COVID-19, SARS-CoV-2, cell therapy, mesenchymal stem cells, P-MSCs, placental mesenchymal stem cells
Type of Study: Original |
Subject:
Hematology and laboratory sciences
Received: 2023/11/11 | Accepted: 2024/01/14 | Published: 2024/02/26
Received: 2023/11/11 | Accepted: 2024/01/14 | Published: 2024/02/26
References
1. Wu Y, Ho W, Huang Y, et al. SARS-CoV-2 is an appropriate name for the new coronavirus. Lancet 2020; 395(10228): 949-50. [DOI]
2. Guan W jie, Ni Z y, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020; 382(18): 1708-20. [DOI]
3. Durand N, Mallea J, Zubair AC. Insights into the use of mesenchymal stem cells in COVID19 mediated acute respiratory failure. NPJ Regen Med 2020; 5(1): 17. [DOI]
4. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 2020; 5(4): 536-544. [DOI]
5. Słomka A, Kowalewski M, Żekanowska E. Coronavirus Disease 2019 (COVID-19): A Short Review on Hematological Manifestations. Pathogens 2020; 9(6): 493. [DOI]
6. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020; 323(11): 1061-9. [DOI]
7. D’Amico F, Baumgart DC, Danese S, et al. Diarrhea During COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and Management. Clin Gastroenterol Hepatol 2020; 18(8): 1663-72. [DOI]
8. Debuc B, Smadja DM. Is COVID-19 a new hematologic disease? Stem Cell Rev Rep 2021; 17(1): 4-8. [DOI]
9. Lamers MM, Haagmans BL. SARS-CoV-2 pathogenesis. Nat Rev Microbiol 2022; 20(5): 270-84. [DOI]
10. Yuan X, Huang W, Ye B, et al. Changes of hematological and immunological parameters in COVID-19 patients. Int J Hematol 2020; 112(4): 553-9. [DOI]
11. Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med 2020; 8(6): e46-e47. [DOI]
12. Golchin A, Seyedjafari E, Ardeshirylajimi A. Mesenchymal Stem Cell Therapy for COVID19: Present or Future. Stem Cell Rev Rep 2020; 16(3): 427-33. [DOI]
13. Shu L, Niu C, Li R, et al. Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells. Stem Cell Res Ther 2020; 11(1): 361. [DOI]
14. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020; 395(10224): 565-74. [DOI]
15. Hashemian SMR, Aliannejad R, Zarrabi M, et al. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series. Stem Cell Res Ther 2021; 12(1): 91. [DOI]
16. Zhang Y, Ding J, Ren S, et al. Intravenous infusion of human umbilical cord Wharton’s jelly-derived mesenchymal stem cells as a potential treatment for patients with COVID-19 pneumonia. Stem Cell Res Ther 2020; 11(1): 207. [DOI]
17. Leng Z, Zhu R, Hou W, et al. Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia. Aging Dis 2020; 11(2): 216-228. [DOI]
18. Sánchez-Guijo F, García-Arranz M, LópezParra M, et al. Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study. EClinicalMedicine 2020; 25: 100454. [DOI]
19. Fischer UM, Harting MT, Jimenez F, et al. Pulmonary Passage is a Major Obstacle for Intravenous Stem Cell Delivery: The Pulmonary First-Pass Effect. Stem Cells Dev 2009; 18(5): 683-92. [DOI]
20. Aghayan HR, Payab M, Mohamadi-Jahani F, et al. GMP-Compliant Production of Human Placenta-Derived Mesenchymal Stem Cells. In: Turksen K, editor. Stem Cells and Good Manufacturing Practices. New York, NY: Springer US, 2020, 213-25. [DOI]
21. Khalifeh Soltani S, Forogh B, Ahmadbeigi N, et al. Safety and efficacy of allogenic placental mesenchymal stem cells for treating knee osteoarthritis: a pilot study. Cytotherapy 2019; 21(1): 54-63. [DOI]
22. Kousha A, Haji Ghasem Kashani M, Vaezi GH, et al. Expression of Neurotrophins in Adipose-derived Stem Cells during in vitro Culture and Posttransplantation in Parkinsonian Rat Model. Iran South Med J 2022; 25(3): 227-239. (Persian) [DOI]
23. Zhu H, Xiong Y, Xia Y, et al. Therapeutic Effects of Human Umbilical Cord-Derived Mesenchymal Stem Cells in Acute Lung Injury Mice. Sci Rep 2017; 7(1): 39889. [DOI]
24. Liang B, Chen J, Li T, et al. Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells: A case report. Medicine (Baltimore) 2020; 99(31): e21429. [DOI]
25. Ramezankhani R, Solhi R, Memarnejadian A, et al. Therapeutic modalities and novel approaches in regenerative medicine for COVID19. Int J Antimicrob Agents 2020; 56(6): 106208. [DOI]
26. Adas G, Cukurova Z, Yasar KK, et al. The Systematic Effect of Mesenchymal Stem Cell Therapy in Critical COVID-19 Patients: A Prospective Double Controlled Trial. Cell Transplant 2021; 30: 9636897211024942. [DOI]
27. Ahangar P, Mills SJ, Cowin AJ. Mesenchymal Stem Cell Secretome as an Emerging Cell-Free Alternative for Improving Wound Repair. Int J Mol Sci 2020; 21(19): 7038. [DOI]
28. Lu D, Xu Y, Liu Q, et al. Mesenchymal Stem Cell-Macrophage Crosstalk and Maintenance of Inflammatory Microenvironment Homeostasis. Front Cell Dev Biol 2021; 9: 681171. [DOI]
29. Divband S, Tasharrofi N, Abroun S, et al. Human Umbilical Cord Mesenchymal Stem CellsDerived Small Extracellular Vesicles Can Be Considered as Cell-Free Therapeutics for Angiogenesis Promotion. Cell J 2022; 24(11): 689-696. [DOI]
30. Omidvar F, Haji Ghasem Kashani M, Tabatabai TS. Expression of Apoptotic Genes in MCF7 Cancer Cells after Induction with Human Adipose Stem Cells Conditioned Medium and Rosemary Extract. Iran South Med J 2023; 25(5): 422-441. (Persian) [Article]
Send email to the article author
| Rights and Permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
